The paradigm shift that began with EMPA-REG OUTCOME and LEADER has led to SGLT2 inhibitors and GLP-1 RA being recognised not only in international diabetes guidelines, but also as an important consideration for patients with T2D in CVD prevention [28–30, 76, 77], HF [133–135] and CKD [41, 102] guidelines, where it has been suggested that these agents should be considered early in the course of diabetes management. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.